Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*

Diabetic Medicine : a Journal of the British Diabetic Association
C J CurrieChris D Poole

Abstract

The purpose of this study was to characterize the financial cost and efficacy of primary care treatment for diabetes in the United Kingdom from 1997 to 2007. Retrospective data were analysed for people with Type 1 and Type 2 diabetes along with matched control subjects using data from The Health Improvement Network. Costs were attributed from published sources and adjusted for price inflation. Type 2 diabetes was analysed by five commonly used treatment regimens. It was possible to identify 126 052 people for inclusion: 11 300 (8.9%) with Type 1 diabetes and 114 752 (91.1%) with Type 2. The overall mean prescribing costs per person per year (pppy) increased markedly for people with diabetes from 1997 to 2007: for Type 1, from 573 pounds to 1014 pounds pppy (+77%), and for Type 2, from 39 pounds to 740 pounds pppy (+89%). In 2007, diabetes-treatment-specific prescribing represented 57% of prescribing costs in Type 1 diabetes and 28% in Type 2 diabetes. In Type 2 diabetes there was a mean of 5.4 primary care consultations in 1997, increasing to 11.5 pppy in 2007 (+112%). In 1997 the total mean cost of primary care treatment for Type 2 diabetes was 602 pounds pppy, increasing to 1080 pounds in 2007. In Type 1 diabetes, the mean gl...Continue Reading

References

Aug 1, 1997·Diabetic Medicine : a Journal of the British Diabetic Association·C J CurrieJ R Peters
Dec 22, 1999·Neurology·A OttM M Breteler
Jul 18, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·A BagustC J Currie
May 10, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·H E MulnierR A Lawrenson
Oct 13, 2006·JAMA : the Journal of the American Medical Association·Joel M GelfandAndrea B Troxel
Oct 21, 2006·Journal of the American Academy of Dermatology·Andrea L NeimannJoel M Gelfand
Oct 27, 2006·Pharmacoepidemiology and Drug Safety·James D LewisBrian L Strom
Jul 3, 2007·Pharmacoepidemiology and Drug Safety·Thomas A BurkeGeorge G Rhoads
Jul 10, 2008·Pharmacoepidemiology and Drug Safety·David J MargolisBrian L Strom
Jun 16, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C L MorganC J Currie
Jul 20, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C J CurrieM Evans

❮ Previous
Next ❯

Citations

Apr 16, 2014·International Journal for Equity in Health·Emma WilkinsonManinder Singh
May 13, 2014·Diabetes Research and Clinical Practice·Charmaine S NgYu Ko
May 16, 2014·Archives of Medical Research·Angélica Castro-RíosNiels Wacher-Rodarte
Jul 26, 2011·Current Medical Research and Opinion·Stephen BruntonAnthony H Barnett
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C Ll MorganC J Currie
Jan 15, 2014·Diabetes, Obesity & Metabolism·S E HoldenC J Currie
May 20, 2014·International Journal of Clinical Practice·H SiddiqueA A Tahrani
Jul 20, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C J CurrieM Evans
Jul 23, 2016·Pediatric Diabetes·Feneli KarachaliouKyriaki Karavanaki
Sep 1, 2016·Health Technology Assessment : HTA·Tracey Jones-HughesRob Anderson
Jan 18, 2015·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Phil McEwanKlas Bergenheim
Apr 11, 2015·Clinical Medicine Insights. Endocrinology and Diabetes·Andreas LieblJean-Francois Yale
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·E A M Gale
Aug 21, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·A M Gray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.